SURVIVAL OUTCOMES IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING THIRD-OR SUBSEQUENT LINE (3L) TREATMENT PRIOR TO THE AVAILABILITY OF PONATINIB

被引：0
|
作者：
Stellato, D. [1 ]
McGarry, L. [2 ]
Huang, H. [2 ]
Hastings, S. [1 ]
Delea, T. [1 ]
机构：
[1] PAI, Brookline, MA USA
[2] ARIAD Pharmaceut Inc, Cambridge, MA USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1055
引用
收藏
页码：434 / 434
页数：1
相关论文
共 50 条
  • [1] Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.
    Stellato, Daniel R.
    McGarry, Lisa
    Huang, Hui
    Hastings, Shaina
    Delea, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Survival Outcomes in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Receiving Third- or Subsequent Line (3L) Treatment
    Stellato, Daniel R.
    McGarry, Lisa
    Huang, Hui
    Hastings, Shaina
    Delea, Thomas E.
    Lipton, Jeffrey H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S311 - S312
  • [3] COST-EFFECTIVENESS ANALYSIS OF PONATINIB IN THE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SWEDEN
    Iannazzo, S.
    McGarry, L.
    Chiroli, S.
    VALUE IN HEALTH, 2015, 18 (07) : A668 - A668
  • [4] A MODEL-BASED ASSESSMENT OF THE BENEFITS AND RISKS OF PONATINIB VERSUS BOSUTINIB IN THIRD-LINE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
    Cartier, S.
    Parthan, A.
    McGarry, L.
    Weinstein, M.
    HAEMATOLOGICA, 2015, 100 : 149 - 150
  • [5] Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Jabbour, Elias
    Apperley, Jane
    Cortes, Jorge
    Rea, Delphine
    Deininger, Michael
    Abruzzese, Elisabetta
    Chuah, Charles
    Deangelo, Daniel J.
    Hochhaus, Andreas
    Lipton, Jeffrey H.
    Mauro, Michael
    Nicolini, Franck
    Pinilla-Ibarz, Javier
    Rosti, Gianantonio
    Rousselot, Philippe
    Shah, Neil P.
    Talpaz, Moshe
    Vorog, Alexander
    Ren, Xiaowei
    Kantarjian, Hagop
    LEUKEMIA, 2024, 38 (03) : 475 - 481
  • [6] Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Jabbour, Elias
    Apperley, Jane
    Cortes, Jorge
    Rea, Delphine
    Deininger, Michael
    Abruzzese, Elisabetta
    Chuah, Charles
    Deangelo, Daniel J.
    Hochhaus, Andreas
    Lipton, Jeffrey H.
    Mauro, Michael
    Nicolini, Franck
    Pinilla-Ibarz, Javier
    Rosti, Gianantonio
    Rousselot, Philippe
    Shah, Neil P.
    Talpaz, Moshe
    Vorog, Alexander
    Ren, Xiaowei
    Kantarjian, Hagop
    LEUKEMIA, 2024, 38 (10) : 2291 - 2291
  • [7] 4-Year Results With Ponatinib by Mutation Status in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): OPTIC Study
    Deininger, Michael
    Apperley, Jane
    Arthur, Christopher Kevin
    Chuah, Charles
    Hochhaus, Andreas
    de Lavallade, Hugues
    Lipton, Jeffrey
    Lomaia, Elza
    McCloskey, James
    Maness, Lori
    Mauro, Michael
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rosti, Gianantonio
    Rousselot, Philippe
    Sutton, Maria Undurraga
    Ren, Xiaowei
    Vorog, Alexander
    Kantarjian, Hagop
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S353 - S354
  • [8] Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
    Talpaz, Moshe
    Cortes, Jorge E.
    Kantarjian, Hagop
    Shah, Neil P.
    Bixby, Dale
    Flinn, Ian
    O'Hare, Thomas
    Hu, Simin
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W.
    Mauro, Michael J.
    BLOOD, 2014, 124 (21)
  • [9] MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB
    Talpaz, M.
    Cortes, J. E.
    Kantarjian, H. M.
    Shah, N. P.
    Bixby, D. L.
    Flinn, I. W.
    O'Hare, T. J.
    Hu, S.
    Rivera, V. M.
    Clackson, T.
    Conlan, M. G.
    Haluska, F. G.
    Druker, B. J.
    Deininger, M. W.
    Mauro, M. J.
    HAEMATOLOGICA, 2015, 100 : 65 - 66
  • [10] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
    Lipton, Jeffrey H.
    Chuah, Charles
    Guerci-Bresler, Agnes
    Rosti, Gianantonio
    Simpson, David
    Assouline, Sarit
    Etienne, Gabriel
    Nicolini, Franck E.
    Le Coutre, Philipp
    Clark, Richard
    Stenke, Leif
    Andorsky, David
    Oehler, Vivian
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Baccarani, Michele
    Cortes, Jorge E.
    Guilhot, Francois
    Hochhaus, Andreas
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Talpaz, Moshe
    Deininger, Michael W.
    BLOOD, 2014, 124 (21)
12345